Pfizer Inc (PFE)
28.78USD
21 May 2013
$0.08 (+0.28%)
$28.96
$28.71
$28.83
$28.31
44,108,264
32,456,596
$31.15
$21.40
PFE
About
Overall
| Beta: | 0.75 |
| Market Cap (Mil.): | $203,575.50 |
| Shares Outstanding (Mil.): | 7,093.22 |
| Dividend: | 0.24 |
| Yield (%): | 3.34 |
Financials
| PFE | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 20.30 | 35.67 | 35.85 |
| EPS (TTM): | 1.41 | -- | -- |
| ROI: | -- | 19.40 | 18.76 |
| ROE: | -- | 20.11 | 19.57 |
Pfizer halts study of lymphoma drug unlikely to help survival
- Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a drug for aggressive non-Hodgkin lymphoma after independent monitors found it was not likely to improve survival.
Pfizer yet to decide on Pain Therapeutics' painkiller
- Pfizer Inc said it could not decide whether to pursue regulatory approval for Pain Therapeutics Inc's painkiller Remoxy, for which the United States Food and Drug Administration sought additional studies.
REUTERS SUMMIT-Drug industry CEOs plotting more carve-outs
(For other news from Reuters Health Summit, click on http://www.reuters.com/summit/Health13)
Pfizer results fall short; company trims profit forecast
- Pfizer Inc reported much lower-than-expected first-quarter sales on Tuesday, hurt by weak demand for its Prevnar 13 vaccine used to prevent pneumonia and other infections, and it trimmed its 2013 profit forecast.
UPDATE 4-Pfizer results fall short; company trims profit forecast
April 30 - Pfizer Inc reported much lower-than-expected first-quarter sales on Tuesday, hurt by weak demand for its Prevnar 13 vaccine used to prevent pneumonia and other infections, and it trimmed its 2013 profit forecast.
Pain Therapeutics, Durect shares soar on Pfizer's Remoxy comments
- Shares of Pain Therapeutics Inc and Durect Corp rose more than 40 percent after partner Pfizer Inc said it is in talks with U.S. health regulators to find a way forward on the companies' painkiller, Remoxy.
Strong pet product sales help Zoetis top estimates
- Zoetis Inc , formerly the animal health subsidiary of U.S. pharmaceuticals giant Pfizer Inc , posted a stronger-than-expected quarterly profit, driven by growth in sales of pet products in the United States.
UPDATE 2-Strong pet product sales help Zoetis top estimates
April 30 - Zoetis Inc, formerly the animal health subsidiary of U.S. pharmaceuticals giant Pfizer Inc , posted a stronger-than-expected quarterly profit, driven by growth in sales of pet products in the United States.
Zoetis profit beats Street on strong pet product sales
- Zoetis Inc , formerly the animal health subsidiary of U.S. pharmaceuticals giant Pfizer Inc , posted a better-than-expected quarterly profit, driven by strong growth in sales of pet products in the United States.
BRIEF-Pfizer shares down 2.7 pct premarket after results
NEW YORK, April 30 - Pfizer Inc : * Shares down 2.7 percent in premarket trading after results, outlook
Competitors
| Price | Change | |
|---|---|---|
| The Procter & Gamble Company (PG.N) | $78.80 | -0.29 |
| Johnson & Johnson (JNJ.N) | $88.59 | +0.58 |
| Novartis AG (NOVN.VX) | CHF72.40 | +0.65 |
| Merck & Co., Inc. (MRK.N) | $47.33 | +2.12 |
| Roche Holding Ltd. (ROG.VX) | CHF251.00 | +4.00 |
| Abbott Laboratories (ABT.N) | $37.72 | -0.09 |
| Bayer AG (BAYGn.DE) | €84.65 | +0.53 |
| Bayer AG (BAYE.F) | -- | -- |
| Sanofi SA (SASY.PA) | €85.14 | +0.83 |
| AstraZeneca plc (AZN.L) | 3,394.50p | +4.00 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (PFE). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
